CIK 0001390478 · Non-accelerated filer<br>Smaller reporting company
SELLAS Life Sciences Group, Inc.
Sign in to watch- Ticker
- SLS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 6462005278
- Business address
- 7 TIMES SQUARE, SUITE 2503, NEW YORK, NY, 10036
- Former names
- GALENA BIOPHARMA, INC., Galena Biopharma, Inc., RXI PHARMACEUTICALS CORP
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2016-06-01 | Dunlap Ryan Former Chief Financial Officer | Option exercise · Stock Option | −30,000 | 0 | ||
| 2016-04-25 | GRAY MARY ANN Director | Grant or award · Stock Option (right to buy) | +200,000 | 200,000 | ||
| 2016-02-23 | Burns John Thomas Principal Accounting Officer | Grant or award · Stock Option (right to buy) | +75,000 | 75,000 | ||
| 2015-12-18 | Nejadnik Bijan Executive VP and CMO | Grant or award · Stock Option (right to buy) | +50,000 | 50,000 | ||
| 2015-12-18 | Knapp Thomas J General Counsel | Grant or award · Stock Option (right to buy) | +225,000 | 225,000 | ||
| 2015-12-18 | SCHWARTZ MARK W. President and CEO | Grant or award · Stock Option (right to buy) | +1,250,000 | 1,250,000 | ||
| 2015-10-30 | Nejadnik Bijan Executive VP and CMO | Grant or award · Stock Option (right to buy) | +350,000 | 350,000 | ||
| 2015-06-25 | Knapp Thomas J General Counsel | Grant or award · Stock Option (right to buy) | +40,000 | 40,000 | ||
| 2015-06-19 | GALLIKER STEPHEN S Director | Grant or award · Stock Option (right to buy) | +100,000 | 100,000 | ||
| 2015-06-19 | Einhorn Irving M. Director | Grant or award · Stock Option (right to buy) | +100,000 | 100,000 | ||
| 2015-06-19 | KRIEGSMAN STEVEN A Director | Grant or award · Stock Option (right to buy) | +100,000 | 100,000 | ||
| 2015-06-19 | Hillsberg Sanford Director | Grant or award · Stock Option (right to buy) | +100,000 | 100,000 | ||
| 2015-06-19 | Nisi Rudolph Director | Grant or award · Stock Option (right to buy) | +100,000 | 100,000 | ||
| 2015-06-19 | Chin Richard Director | Grant or award · Stock Option (right to buy) | +100,000 | 100,000 | ||
| 2015-06-19 | Ashton William Director | Grant or award · Stock Option (right to buy) | +100,000 | 100,000 | ||
| 2015-01-16 | SCHWARTZ MARK W. President & CEO | Grant or award · Stock Option (right to buy) | +550,000 | 550,000 | ||
| 2015-01-16 | Dunlap Ryan VP, Chief Financial Officer | Grant or award · Stock Option (right to buy) | +125,000 | 125,000 | ||
| 2015-01-16 | Kivinski Margaret VP and General Counsel | Grant or award · Stock Option (right to buy) | +50,000 | 50,000 | ||
| 2014-12-31 | SCHWARTZ MARK W. President & CEO | Other acquisition | +3,846 | $1.28 | $5K | 415,972 |
| 2014-12-31 | Dunlap Ryan VP, Chief Financial Officer | Other acquisition | +3,846 | $1.28 | $5K | 11,650 |
Page 12 of 17 · 324 trades